Methadone

American Journal of Hospice and Palliative Medicine

Volumn 25, Issue 2, 2008, Pages 146-150

  Chhabra, Shalini ^a   Bull, Janet ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b Four Seasons Hospice and Palliative Care   (United States)

Author keywords

Bioavailability; Equianalgesic dosing; Indications; Methadone toxicity; Pharmacodynamics

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; DRUG ADMINISTRATION; DRUG MONITORING; HALF LIFE TIME; HOSPICE CARE; HUMAN; INTESTINE ABSORPTION; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PAIN; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HALF-LIFE; HOSPICE CARE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; METHADONE; PAIN; TISSUE DISTRIBUTION;

EID: 41949107022     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909107312597     Document Type: Article

References (44)

1. Reisine T., Pasternak G. Opioid analgesics and antagonists. In: Limbird LE, Hardman JG, eds. Goodman and Gilman's The Pharmacologic Basis Therapeutics. 9 th ed. New York, NY: McGraw-Hill ; 1996: 521-555.
2. Ebert B., Thorkildsen C., Anderson S., Dhristrup LL, Hjeds H. Opioid analgesics as noncompetitive N-methylD-aspartate (NMDA) antagonists. Biochem Pharmacol. 1998 ; 56 (5). 553-559.
3. Liu JG, Anand KJ Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence. Brain Res Brain Res Rev. 2001 ; 38 (1-2). 1-19.
4. Mao J. NMDA and opioid receptors: their interactions in intinociception, tolerance and neuroplasticity. Brain Res Brain Res Rev. 1999 ; 30 (3). 289-304.
5. De Castro J., Aguirre C., Rodriguez-Sasiain JM, Gomez E., Garrido MJ, Calvo R. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharm Drug Dispos. 1996 ; 17 (7). 551-563.
6. Ferrari A., Coccia CP, Bertolini A., Sternieri E. Methadone: metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 ; 50 (6). 551-559.
7. Dale O., Sheffels P., Kharasch ED Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol. 2004 ; 58 (2). 156-162.
8. Grabinski PY, Kaiko RF, Rogers AG, Houde RW Plasma levels and analgesia following deltoid and gluteal injections of methadone and morphine. J Clin Pharmacol. 1983 ; 23 (1). 48-55.
9. De Vos JW, Geerlings PJ, van den Brink W., Ufkes JG, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol. 1995 ; 48 (5). 361-366.
10. Malpas TJ, Darlow BA, Lennox R., Horwood LJ Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynaecol. 1995 ; 35 (2). 175-177.
11. Wojnar-Horton RE, Kristensen JH, Yapp P., Ilett KF, Dusci LJ, Hackett LP Methadone distribution and excretion into breast milk of clients in a methadone maintenance programme. Br J Clin Pharmacol. 1997 ; 44 (6). 543-547.
12. Begg EJ, Malpas TJ, Hackett LP, Ilett KF Distribution of R- and S- methadone into human breast milk during multiple, medium to high oral dosing. Br J Clin Pharmacol. 2001 ; 52 (6). 681-685.
13. Verbely K., Volavka J., Mule S., Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther. 1975 ; 18 (2). 180-190.
14. Rostami-Hodjegan A., Wolff K., Hay AW, Raistrick D., Calvert R., Tucker GT Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999 ; 48 (1). 43-52.
15. Baselt RC, Casarett LJ Urinary excretion of methadone in man. Clin Pharmacol Ther. 1972 ; 13 (1). 64-70.
16. Beckett AH, Taylor JF, Casy AF, Hassan MM The bio-transformation of methadone in man: synthesis and identification of a major metabolite. J Pharm Pharmacol. 1968 ; 20 (10). 754-762.
17. Anggard E., Gunne LM, Homstrand J., McMahon RE, Sandberg CG, Sullivan HR Disposition of methadone in methadone maintenance. Clin Pharmacol Ther. 1975 ; 17 (3). 258-266.
18. Iribarne C., Berthou F., Baird S., et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 ; 9 (2). 365-373.
19. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P4503A4 in N-demethylation of L-〈-acetylmethadol (LAAM), nor-LAAM, and methadone. Drug Metab Dispos. 1997 ; 25 (12). 1347-1353.
20. Peng PW, Tumber PS, Gourlay D. Review article: peri-operative pain management of patients on methadone therapy [in French]. Can J Anaesth. 2005 ; 52 (5). 513-523.
21. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther. 1972 ; 13 (6). 923-930.
22. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther. 1987 ; 41 (4). 392-401.
23. Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980 ; 5 (3). 197-205.
24. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004 ; 28 (5). 497-504.
25. Anderson RJ, Schrier RW Clinical Use of Drugs in Patients With Kidney and Liver Disease. Philadelphia, PA: WB Saunders Co ; 1981.
26. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther. 1981 ; 30 (3). 353-362.
27. Izzo AA Drug interactions with St. John's wort (Hypericum perforatum): a review of clinical evidence. Int J Clin Pharmacol Ther. 2004 ; 42 (3). 139-148.
28. Bart PA, Rizzardi PG, Gallant S., et al. Methadone blood concentrations are decreased by administration of abacavir plus amprenavir. Ther Drug Monit. 2001 ; 23 (5). 553-555.
29. Smith PF, Kearney BP, Liaw S., et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy. 2004 ; 24 (8). 970-977.
30. Denson DD, Concilus RR, Warden G., Raj PP Pharmacokinetics of continuous intravenous infusion of methadone in early post-burn period. J Clin Pharmacol. 1990 ; 30 (1). 70-75.
31. Pond SM, Kreek MJ, Tong TG, Raghunath J., Benowitz NL Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985 ; 233 (1). 1-6.
32. Jarvis MA, Wu- Pong S., Kniseley JS, Schnoll SH Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999 ; 18 (4). 51-61.
33. Lugo RA, MacLaren R., Cash J., Pribble CG, Vernon DD Enteral methadone to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in PICU. Pharmacotherapy. 2001 ; 21 (12). 1566-1573.
34. Tobias JD, Deshpande JK, Gregory DF Outpatient therapy of iatrogenic drug dependency following prolonged sedation in pediatric intensive care unit. Intensive Care Med. 1994 ; 20 (7). 504-507.
35. Eap CB, Buclin T., Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002 ; 41 (14). 1153-1193.
36. College of Physicians & Surgeons of Ontario Web site. Evidence-based recommendations for medical management of chronic non-malignant pain: reference guide for physicians. November 2000. http://www.cpso.on.ca/Publications/pain. htm. Accessed December 7, 2007.
37. Ayonrinde OT, Bridge DT The rediscovery of methadone for cancer pain management. Med J Aust. 2000 ; 173 (10). 536-540.
38. Bruera E., Neumann CM Role of methadone in the management of pain in cancer patients. Oncology. 1999 ; 13 (9). 1275-1288, 1291.
39. Lawlor PG, Turner KS, Hanson J., Bruera ED Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer. 1998 ; 82 (6). 1167-1173.
40. Morley JS, Makin MK Comments on Ripamonti et al, Pain, 70 (1997) 109-115.
41. Beaver WT, Wallenstein SL, Iloude RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally and parentally administered methadone. Clin Pharmacol Ther. 1967 ; 8 (3). 415-426.
42. Ettinger DS, Vitale PJ, Trump DL Important clinical pharmacological considerations in the use of methadone in cancer patients. Cancer Treat Rep. 1979 ; 63 (3). 457-459.
43. Berkowitz BA The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet. 1976 ; 1 (3). 219-230.
44. Tenenbein M. Continuous naloxone infusion for opiate poisoning in infancy. J Pediatr. 1984 ; 105 (4). 645-648.